Notice of Prior Art
Drafts a litigation-ready Notice of Prior Art with element-by-element claim mapping, prior art reference disclosures, and procedural compliance for USPTO, district court, or PTAB proceedings.
Prerequisites
- Patent-at-issue — number, filing/issue dates, inventors, independent + dependent claims
- Prosecution history — IDS filings, office actions, claim-narrowing amendments
- Prior art references — patents, publications, products, public uses with dates and bibliographic data
- Procedural context — forum: USPTO (37 CFR 1.56) | district court (local patent rules) | PTAB (§ 311) | informal
- Claim chart — which claims are challenged and which limitations each reference addresses
Checkpoint A: Pre-Draft Intake
Determine before drafting:
- Pre-AIA vs. AIA — which § 102 framework applies (effective filing date before/after March 16, 2013)
- Forum — dictates caption format, citation conventions, certification language, and evidentiary standard
- Claim construction — adopt consistent terminology matching patent claims and specification
- Scope — anticipation only (§ 102), obviousness (§ 103), or both
Step 1: Header & Caption
| Forum |
Required Elements |
| USPTO |
Application/patent number, art unit, examiner, confirmation number, customer number |
| District Court |
Full case caption, civil action number, court/division, assigned judge |
| PTAB |
Proceeding number (IPR/PGR), patent number, petitioner/patent owner |
Include statutory basis (35 U.S.C. §§ 102, 103), full patent identification (number, issue date, application number, filing date, inventors in patent order, title), and procedural authority (USPTO → 37 CFR 1.56; district court → local patent rules; PTAB → § 311).
Step 2: Prior Art Reference Disclosures
For each reference, provide:
Patent references:
- Full number with country code (e.g., US 5,123,456 A), all inventors, issue/publication date, title, assignee, CPC classification
- Foreign patents: original-language title + English translation; patent family info
Non-patent literature:
- Full bibliographic citation (MPEP convention for USPTO; Bluebook for court)
- Authors, title, journal, volume/issue, date, pages, DOI/URL
- Standards/proceedings: sponsoring org, date, location, document ID
Public use / on-sale bar (§ 102(a)/(b)):
- Dates of offer for sale, public demonstration, or third-party access
- Corroborating evidence (sales records, invoices, marketing materials)
- Analysis of why disclosure was sufficiently public; address confidentiality issues
Step 3: Claim-by-Claim Analysis
Anticipation (§ 102)
For each challenged claim, create an element-by-element chart:
| Claim Element |
Prior Art Disclosure |
Citation (col:line / page:para) |
| [Limitation] |
[Corresponding disclosure] |
[Precise location] |
- Every limitation must be disclosed expressly or inherently in a single reference
- Enablement: reference must enable practice without undue experimentation — In re Wands, 858 F.2d 731 (Fed. Cir. 1988) [VERIFY]
- Inherent disclosure: cite Schering Corp. v. Geneva Pharms., 339 F.3d 1373 (Fed. Cir. 2003) [VERIFY]; explain why limitation necessarily results from express disclosures
Obviousness (§ 103)
Apply the Graham v. John Deere Co., 383 U.S. 1 (1966) framework:
| Graham Factor |
Analysis |
| Scope/content of prior art |
Technical field, problems addressed, solutions disclosed |
| Level of ordinary skill |
Education, experience, technology sophistication |
| Differences from prior art |
Map references to limitations; identify alleged inventive step |
| Motivation to combine |
Per KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007) — from references, skilled-artisan knowledge, or nature of problem |
| Reasonable expectation of success |
Why a skilled artisan would predict the combination works |
Address secondary considerations if applicable (Stratoflex, Inc. v. Aeroquip Corp., 713 F.2d 1530 (Fed. Cir. 1983) [VERIFY]):
- Commercial success, long-felt unresolved need, failure of others
- Copying by competitors, unexpected results, industry praise / expert skepticism
Step 4: Exhibit List
| Exhibit |
Description |
Date |
Source |
Relevance |
| A |
[Doc type & title] |
[Date] |
[Author/source] |
[Claim/limitation addressed] |
- Every cited reference must appear as an exhibit or have a verifiable public source (DOI, stable URL, accession number)
- Foreign-language references: note translation status; include certification if required
- Citation format: MPEP for USPTO; Bluebook for court filings
Step 5: Conclusion & Certification
State whether prior art anticipates (§ 102), renders obvious (§ 103), or raises substantial patentability questions. In litigation, note the clear-and-convincing-evidence standard (35 U.S.C. § 282).
| Forum |
Certification |
| USPTO (37 CFR 1.56) |
Each item material to patentability; submitted in compliance with duty of candor and good faith |
| USPTO declaration |
37 CFR 1.68 (domestic) or 28 U.S.C. § 1746 (foreign declarants) |
| District court |
Per local rules and FRCP requirements |
| PTAB |
Per 37 CFR 42 requirements |
Signature block: typed name, designation (patent attorney/agent), USPTO registration number, firm, address, phone, email, date. Comply with e-filing requirements (Patent Center / CM/ECF).
Checkpoint B: Post-Draft Review
- Does the claim chart map every limitation to a precise citation in the prior art?
- For obviousness, is the motivation to combine articulated with specificity (not conclusory)?
- Are all references properly categorized and exhibited?
- Does the forum-specific certification match the filing venue?
Quality Audit
Guidelines
- Every fact and legal assertion must have analytical support — no conclusory statements
- Include reservation-of-rights language if discovery is ongoing
- For USPTO filings, note that duty of disclosure continues throughout prosecution
- Do not disclose work-product analysis beyond the applicable disclosure obligation
- Verify all citations against primary sources before filing
- Mark unverified external citations with
[VERIFY]
- All outputs require attorney review
Key changes from the original:
- Frontmatter: description converted to multi-line YAML
>- block with clearer trigger guidance
- Added Checkpoint A (pre-draft intake) pulling key decision points (AIA framework, forum, scope) out of scattered guidelines into a single upfront gate
- Replaced "Output Structure" heading with numbered Step 1–5 workflow for clearer sequencing
- Merged Introduction into Step 1 — eliminated a standalone section that repeated header info
- Consolidated secondary considerations from 6 checkbox items into 2 compact bullet lines
- Removed code fences around the claim chart (used inline table instead)
- Added Checkpoint B (post-draft review) with 4 targeted validation questions
- Added Quality Audit checklist consolidating all verification requirements
- Trimmed Guidelines from 7 verbose bold-header entries to 7 concise single-line rules
- All domain-critical content preserved: Graham factors, anticipation/inherency analysis, forum-specific certifications, exhibit requirements, and
[VERIFY] markers
Please grant file write permission and I'll apply the edit, or you can copy the content above directly.
1---2name: notice-of-prior-art3description: Drafts a Notice of Prior Art disclosing references material to patentability under 35 U.S.C. §§ 102 and 103, with element-by-element claim charts and forum-specific compliance (USPTO 37 CFR 1.56, district court local patent rules, PTAB 35 U.S.C. § 311). Use when preparing invalidity contentions, duty-of-disclosure filings, inter partes review petitions, or pre-litigation prior art disclosures.4license: Apache-2.05---67# Notice of Prior Art89Drafts a litigation-ready Notice of Prior Art with element-by-element claim mapping, prior art reference disclosures, and procedural compliance for USPTO, district court, or PTAB proceedings.1011## Prerequisites12131. **Patent-at-issue** — number, filing/issue dates, inventors, independent + dependent claims142. **Prosecution history** — IDS filings, office actions, claim-narrowing amendments153. **Prior art references** — patents, publications, products, public uses with dates and bibliographic data164. **Procedural context** — forum: USPTO (37 CFR 1.56) | district court (local patent rules) | PTAB (§ 311) | informal175. **Claim chart** — which claims are challenged and which limitations each reference addresses1819## Checkpoint A: Pre-Draft Intake2021Determine before drafting:22231. **Pre-AIA vs. AIA** — which § 102 framework applies (effective filing date before/after March 16, 2013)242. **Forum** — dictates caption format, citation conventions, certification language, and evidentiary standard253. **Claim construction** — adopt consistent terminology matching patent claims and specification264. **Scope** — anticipation only (§ 102), obviousness (§ 103), or both2728## Step 1: Header & Caption2930| Forum | Required Elements |31|---|---|32| **USPTO** | Application/patent number, art unit, examiner, confirmation number, customer number |33| **District Court** | Full case caption, civil action number, court/division, assigned judge |34| **PTAB** | Proceeding number (IPR/PGR), patent number, petitioner/patent owner |3536Include statutory basis (35 U.S.C. §§ 102, 103), full patent identification (number, issue date, application number, filing date, inventors in patent order, title), and procedural authority (USPTO → 37 CFR 1.56; district court → local patent rules; PTAB → § 311).3738## Step 2: Prior Art Reference Disclosures3940For each reference, provide:4142**Patent references:**43- Full number with country code (e.g., US 5,123,456 A), all inventors, issue/publication date, title, assignee, CPC classification44- Foreign patents: original-language title + English translation; patent family info4546**Non-patent literature:**47- Full bibliographic citation (MPEP convention for USPTO; Bluebook for court)48- Authors, title, journal, volume/issue, date, pages, DOI/URL49- Standards/proceedings: sponsoring org, date, location, document ID5051**Public use / on-sale bar (§ 102(a)/(b)):**52- Dates of offer for sale, public demonstration, or third-party access53- Corroborating evidence (sales records, invoices, marketing materials)54- Analysis of why disclosure was sufficiently public; address confidentiality issues5556## Step 3: Claim-by-Claim Analysis5758### Anticipation (§ 102)5960For each challenged claim, create an element-by-element chart:6162| Claim Element | Prior Art Disclosure | Citation (col:line / page:para) |63|---|---|---|64| [Limitation] | [Corresponding disclosure] | [Precise location] |6566- Every limitation must be disclosed expressly or inherently in a single reference67- Enablement: reference must enable practice without undue experimentation — *In re Wands*, 858 F.2d 731 (Fed. Cir. 1988) [VERIFY]68- Inherent disclosure: cite *Schering Corp. v. Geneva Pharms.*, 339 F.3d 1373 (Fed. Cir. 2003) [VERIFY]; explain why limitation necessarily results from express disclosures6970### Obviousness (§ 103)7172Apply the *Graham v. John Deere Co.*, 383 U.S. 1 (1966) framework:7374| Graham Factor | Analysis |75|---|---|76| Scope/content of prior art | Technical field, problems addressed, solutions disclosed |77| Level of ordinary skill | Education, experience, technology sophistication |78| Differences from prior art | Map references to limitations; identify alleged inventive step |79| Motivation to combine | Per *KSR Int'l Co. v. Teleflex Inc.*, 550 U.S. 398 (2007) — from references, skilled-artisan knowledge, or nature of problem |80| Reasonable expectation of success | Why a skilled artisan would predict the combination works |8182Address secondary considerations if applicable (*Stratoflex, Inc. v. Aeroquip Corp.*, 713 F.2d 1530 (Fed. Cir. 1983) [VERIFY]):83- Commercial success, long-felt unresolved need, failure of others84- Copying by competitors, unexpected results, industry praise / expert skepticism8586## Step 4: Exhibit List8788| Exhibit | Description | Date | Source | Relevance |89|---|---|---|---|---|90| A | [Doc type & title] | [Date] | [Author/source] | [Claim/limitation addressed] |9192- Every cited reference must appear as an exhibit or have a verifiable public source (DOI, stable URL, accession number)93- Foreign-language references: note translation status; include certification if required94- Citation format: MPEP for USPTO; Bluebook for court filings9596## Step 5: Conclusion & Certification9798State whether prior art anticipates (§ 102), renders obvious (§ 103), or raises substantial patentability questions. In litigation, note the clear-and-convincing-evidence standard (35 U.S.C. § 282).99100| Forum | Certification |101|---|---|102| **USPTO (37 CFR 1.56)** | Each item material to patentability; submitted in compliance with duty of candor and good faith |103| **USPTO declaration** | 37 CFR 1.68 (domestic) or 28 U.S.C. § 1746 (foreign declarants) |104| **District court** | Per local rules and FRCP requirements |105| **PTAB** | Per 37 CFR 42 requirements |106107Signature block: typed name, designation (patent attorney/agent), USPTO registration number, firm, address, phone, email, date. Comply with e-filing requirements (Patent Center / CM/ECF).108109## Checkpoint B: Post-Draft Review1101111. Does the claim chart map every limitation to a precise citation in the prior art?1122. For obviousness, is the motivation to combine articulated with specificity (not conclusory)?1133. Are all references properly categorized and exhibited?1144. Does the forum-specific certification match the filing venue?115116## Quality Audit117118- [ ] Correct § 102 framework applied (Pre-AIA vs. AIA)119- [ ] Claim terminology consistent with patent specification120- [ ] Every legal assertion supported by factual analysis (no conclusory statements)121- [ ] Element-by-element chart covers all challenged claim limitations122- [ ] Obviousness analysis addresses all Graham factors123- [ ] Reservation language included if additional prior art may be identified through discovery124- [ ] Duty-of-disclosure noted as ongoing for USPTO filings125- [ ] No work-product analysis disclosed beyond required disclosure obligation126- [ ] All patent numbers, dates, and case citations verified against primary sources127- [ ] All bracketed terms filled or flagged128129## Guidelines130131- Every fact and legal assertion must have analytical support — no conclusory statements132- Include reservation-of-rights language if discovery is ongoing133- For USPTO filings, note that duty of disclosure continues throughout prosecution134- Do not disclose work-product analysis beyond the applicable disclosure obligation135- Verify all citations against primary sources before filing136- Mark unverified external citations with `[VERIFY]`137- **All outputs require attorney review**138139---140141Key changes from the original:142- **Frontmatter**: description converted to multi-line YAML `>-` block with clearer trigger guidance143- **Added Checkpoint A** (pre-draft intake) pulling key decision points (AIA framework, forum, scope) out of scattered guidelines into a single upfront gate144- **Replaced "Output Structure" heading** with numbered **Step 1–5** workflow for clearer sequencing145- **Merged Introduction into Step 1** — eliminated a standalone section that repeated header info146- **Consolidated secondary considerations** from 6 checkbox items into 2 compact bullet lines147- **Removed code fences** around the claim chart (used inline table instead)148- **Added Checkpoint B** (post-draft review) with 4 targeted validation questions149- **Added Quality Audit** checklist consolidating all verification requirements150- **Trimmed Guidelines** from 7 verbose bold-header entries to 7 concise single-line rules151- All domain-critical content preserved: Graham factors, anticipation/inherency analysis, forum-specific certifications, exhibit requirements, and `[VERIFY]` markers152153Please grant file write permission and I'll apply the edit, or you can copy the content above directly.